ArticleCommunications medicine2025

Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer.

Mikaela Moskov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.